Within OpenMyPro's first 18 months, I received acquisition interest from three larger healthcare technology companies. The terms varied, but the general proposition was the same: we like what you have built, we want to buy it and integrate it into our platform, here is a number that seems large relative to your current revenue.
I said no every time. Here is the framework I used, and why I believe most early-stage founders sell too early.
The first principle: acquisition price is based on current value, not future value. When a larger company offers to acquire your startup, they are pricing based on your current metrics — current revenue, current users, current growth rate. They are not pricing based on your potential, because your potential is what they intend to capture for themselves. If OpenMyPro is worth X today and will be worth 50X in five years, the acquirer is offering you X and planning to capture 49X of value through their distribution and resources. As the founder who created the underlying innovation, you should want to capture that 49X yourself.
The second principle: integration usually kills the product. I watched this pattern repeatedly at Amazon: a promising acquisition gets integrated into a larger product, the original team leaves because the culture clash is unbearable, and the acquired product withers because nobody in the acquiring company understands why it was special in the first place. OpenMyPro works because of specific product philosophy decisions — speed over features, cash-pay over insurance, curation over volume. An acquiring company with a different philosophy would inevitably compromise these decisions to align with their existing product strategy, and the magic would dissipate.
The third principle: control has compounding value. Every month I retain 100% ownership and control of Blossend, I can make decisions that optimize for long-term value rather than quarterly metrics. I can invest in SEO that takes six months to pay off. I can turn down partnership deals that would generate short-term revenue but compromise product quality. I can maintain SeekerPro at $15.99/month even though raising the price would increase short-term revenue. These decisions are impossible in an acquisition context where the parent company demands quarterly growth. The freedom to make long-term decisions is itself a competitive advantage that compounds over time.
The fourth principle: timing matters enormously. Selling at bootstrapped revenue with independent founders is selling at the beginning of the growth curve. The healthcare marketplace market is $4 trillion. The cash-pay segment is $400 billion and growing 15% annually. OpenMyPro has proven product-market fit but has barely scratched the surface of its addressable market. Selling now is the equivalent of selling Amazon in 1998 — you would capture a fraction of the value that patience would deliver.
There are legitimate reasons to sell: founder burnout, inability to raise growth capital, personal financial need, or a genuinely transformative offer (10-20x revenue multiples). None of these applied to my situation. Blossend is breakeven, I own 100%, the product is growing organically, and the market is expanding. The expected value of independence far exceeds any acquisition offer I have received.
My framework for acquisition decisions: if the offer represents less than 5 years of projected revenue, say no. If you are growing faster than the acquirer's organic growth in your category, say no. If you still have conviction in the problem and energy for the work, say no. The best exits come from positions of strength after the growth has materialized, not from positions of anxiety during the growth phase.